THE LIBRARY: WHITEPAPER
Mitigating Phase 2 Development Risks
Phase 2 is the end of the road for many molecules and for others the source of later delays and denials. Learn techniques for mitigating the risks that threaten your development program in the new white paper, Mitigating Phase 2 Development Risks: Design and Operational Strategies and Case Studies for Phase 2 Success. Download the white paper today!
Latest Commentary
Combating HIV: The future of therapeutic vaccines
10 promising therapeutic vaccines in 2012
The 20 top-selling vaccines in H1 2012
GeoVax: Meeting the HIV vaccine challenge
Wishing you a happy HIV Vaccine Awareness Day
more
EVENTS
- FierceBiotech Executive Breakfast: Fast Phase IIIs October 21, 2014 — Boston, MA — Sponsored by Covance and INC Research
- BioBasics: Biotech for the Non-ScientistOctober 23-24 — Boston, MA
- Drug Development Boot Camp - November 19-20, 2014, Boston, MANovember 19-20, 2014 — Boston, MA — Hosted by Harvard University OTD and Speid & Associates, Inc.
Press Releases
- Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data
- BBK Worldwide Raises Growth Capital
- Sequenom Laboratories Presents New Data Supporting The Accuracy Of The MaterniT21® Plus Laboratory Developed Test In Clinical Setting
- ICON Plc Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for up to $100 Million
- New OptiPactâ„¢ Technology Introduced By Catalent
- More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.